Every material Form 8-K InnovAge Holding Corp. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
InnovAge reported fiscal first-quarter 2027 results for the period ended September 30, 2026, with total revenues of $264.8 million, up 12.1% from $236.1 million a year earlier. Net income attributable to InnovAge was $19.6 million, or $0.14 per share, compared with $8.0 million, or $0.06 per share, a year earlier. The company confirmed its full fiscal 2027 guidance, which calls for total revenues of $1,050 million to $1,085 million and Adjusted EBITDA of $105 million to $115 million.
Total revenues of $264.8 million, up 12.1% from $236.1 million in the prior-year quarter
Net income attributable to InnovAge of $19.6 million, or $0.14 per share, versus $8.0 million, or $0.06 per share
Adjusted EBITDA of $31.3 million, up from $17.6 million, with an 11.8% margin
Fiscal 2027 guidance confirmed: total revenues of $1,050 million to $1,085 million and Adjusted EBITDA of $105 million to $115 million
InnovAge disclosed an underwriting agreement dated September 22, 2026, under which a selling shareholder agreed to sell 10,000,000 shares of common stock at $9.25 per share through underwriters including Barclays, Goldman Sachs and Wells Fargo. The company says it will receive no proceeds, and shares were delivered on September 24, 2026. The sale is by an existing shareholder rather than new company capital, so it affects share supply and ownership rather than the company's own funding.
Selling shareholder agreed to sell 10,000,000 shares at $9.25 per share to the underwriters
Underwriters have a 30-day option, from September 22, 2026, to buy up to an additional 1,500,000 shares
InnovAge will not receive any proceeds from the sale of the shares
Shares were delivered against payment on September 24, 2026
InnovAge reported fiscal 2026 revenue of $989.7 million, up about 15.9% from $853.7 million, and a net loss attributable to the company of $2.5 million, or $0.02 per share, versus $30.3 million, or $0.22 per share, a year earlier. The company also issued fiscal 2027 guidance calling for revenue of $1,050 million to $1,085 million and Adjusted EBITDA of $105 million to $115 million, but it accrued $52.4 million in litigation losses for the year, which weighs on shareholder results.
Fiscal 2026 Adjusted EBITDA was $94.6 million, up from $34.5 million in fiscal 2025; the margin was 9.6%.
Fourth-quarter net income attributable to InnovAge was $8.3 million, or $0.06 per share, compared with a loss of $0.8 million a year earlier.
Fiscal 2026 litigation costs and settlements totaled $57.0 million, including $52.4 million of accrued losses for potential resolutions or paid settlements.
Fiscal 2027 guidance: census of 8,625 to 8,850 participants, total revenues of $1,050 million to $1,085 million, and Adjusted EBITDA of $105 million to $115 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every InnovAge Holding Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →